Cilofexor (formerly GS-9674), a small-molecule non-steroidal agonist of FXR, significantly reduced hepatic steatosis, liver biochemical marker, and serum bile acid levels, but did not improve liver fibrosis or stiffness after 24 weeks of treatment (NCT02854605) (76). This evidence concerns the gene NR1H4 and fatty liver disease.